Elicio Therapeutics Inc
ELTX11.320USD
-0.145-1.26%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
184.10MMarket Cap
LossP/E TTM
More Details of Elicio Therapeutics Inc Company
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immuno therapeutics directly to the lymph nodes (brain center) of the immune system. The Company's lead product candidate, ELI-002, is being developed to treat cancers driven by kirsten rat sarcoma (KRAS). It is conducting a Phase I/II clinical trial of ELI-002 (AMPLIFY-201). Its ELI-007, is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers. Its AMP platform has broad potential applications for the treatment or prevention of cancer, infectious diseases and other diseases.
Company Info
Ticker SymbolELTX
Company nameElicio Therapeutics Inc
IPO dateFeb 05, 2021
CEOMr. Robert (Bob) Connelly
Number of employees32
Security typeOrdinary Share
Fiscal year-endFeb 05
Address451 D Street, 5Th Floor
CityBOSTON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02459
Phone18572090050
Websitehttps://elicio.com/
Ticker SymbolELTX
IPO dateFeb 05, 2021
CEOMr. Robert (Bob) Connelly
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
-5.71%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
12.72K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
381.00
--
Dr. Julian Adams, Ph.D.
Dr. Julian Adams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
Ms. Carol Ashe
Ms. Carol Ashe
Independent Director
Independent Director
--
--
Dr. Allen R. Nissenson, M.D.
Dr. Allen R. Nissenson, M.D.
Independent Director
Independent Director
--
--
Dr. Robert R. Ruffolo, Jr.
Dr. Robert R. Ruffolo, Jr.
Independent Director
Independent Director
--
--
Mr. Robert (Bob) Connelly
Mr. Robert (Bob) Connelly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
-5.71%
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
12.72K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
381.00
--
Dr. Julian Adams, Ph.D.
Dr. Julian Adams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
GKCC, LLC
33.15%
Actyus Private Equity SGIIC, S.A.
5.24%
Knoll Capital Management, LLC
3.86%
Clal Biotechnology Industries Ltd
2.95%
The Vanguard Group, Inc.
2.78%
Other
52.02%
Shareholders
Shareholders
Proportion
GKCC, LLC
33.15%
Actyus Private Equity SGIIC, S.A.
5.24%
Knoll Capital Management, LLC
3.86%
Clal Biotechnology Industries Ltd
2.95%
The Vanguard Group, Inc.
2.78%
Other
52.02%
Shareholder Types
Shareholders
Proportion
Corporation
38.39%
Investment Advisor
4.01%
Hedge Fund
3.98%
Holding Company
2.95%
Individual Investor
1.62%
Investment Advisor/Hedge Fund
1.54%
Research Firm
0.11%
Other
47.40%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
59
8.75M
54.70%
+649.27K
2025Q1
71
8.88M
57.84%
+3.95M
2024Q4
66
3.95M
32.81%
+187.04K
2024Q3
70
4.16M
40.61%
+80.64K
2024Q2
82
4.28M
44.94%
+434.22K
2024Q1
108
4.00M
44.25%
+126.75K
2023Q4
114
4.22M
52.86%
+1.57M
2023Q3
132
2.88M
52.57%
+376.65K
2023Q2
138
2.82M
63.05%
+1.05M
2023Q1
137
1.45M
48.19%
-243.12K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
GKCC, LLC
5.42M
33.86%
--
--
Jun 03, 2025
Actyus Private Equity SGIIC, S.A.
856.38K
5.35%
+268.56K
+45.69%
Mar 31, 2025
Knoll Capital Management, LLC
630.91K
3.94%
--
--
Mar 31, 2025
Clal Biotechnology Industries Ltd
481.73K
3.01%
-52.31K
-9.80%
Apr 09, 2024
The Vanguard Group, Inc.
321.69K
2.01%
+75.87K
+30.86%
Mar 31, 2025
Venkatesan (Jay R)
170.22K
1.06%
-10.31K
-5.71%
Mar 24, 2025
Geode Capital Management, L.L.C.
77.47K
0.48%
+6.75K
+9.54%
Mar 31, 2025
Northern Trust Investments, Inc.
51.85K
0.32%
+21.09K
+68.53%
Mar 31, 2025
Arena Investors, LP
50.00K
0.31%
+50.00K
--
Jun 30, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Date
Type
Ratio
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
Jun 01, 2023
Merger
10→1
